for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Madrigal Pharmaceuticals Inc

MDGL.OQ

Latest Trade

94.98USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

82.39

 - 

231.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
94.98
Open
--
Volume
--
3M AVG Volume
4.10
Today's High
--
Today's Low
--
52 Week High
231.09
52 Week Low
82.39
Shares Out (MIL)
15.43
Market Cap (MIL)
1,465.19
Forward P/E
-16.08
Dividend (Yield %)
--

Latest Developments

More

Madrigal Pharmaceuticals Reports 2019 Q2 Loss Per Share $1.28

Madrigal Pharmaceuticals Inc - QTRLY Net Loss $0.98 Per Share

Madrigal Pharmaceuticals To Present Additional Analyses Of Data From Phase 2 NASH Study With MGL-3196

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Industry

Biotechnology & Drugs

Contact Info

200 Barr Harbor Dr Ste 400

+1.404.3809263

http://www.madrigalpharma.com

Executive Leadership

Paul A. Friedman

Chairman of the Board, Chief Executive Officer

Marc R. Schneebaum

Chief Financial Officer, Senior Vice President

Rebecca A. Taub

President of Research & Development, Director

Frederick B. Craves

Lead Independent Director

Kenneth M. Bate

Independent Director

Key Stats

2.15 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-5.070

2017

-2.540

2018

-2.220

2019(E)

-5.827
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-11.61
Return on Equity (TTM)
-11.39

Latest News

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

Madrigal Pharma explores sale: Bloomberg

Madrigal Pharmaceuticals Inc <MDGL.O> is exploring a sale, Bloomberg reported on Wednesday, citing people familiar with the matter, nearly three weeks after the company reported mid-stage data from its drug to treat non-alcoholic steatohepatitis or NASH.

Madrigal Pharma more than doubles after liver drug study success

Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.

Madrigal Pharma's liver disease drug succeeds in mid-stage trial

Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.

BRIEF-Madrigal Pharmaceuticals Reports Qtrly Loss Per Share Of $0.45

* MADRIGAL PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS

BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​

* MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

BRIEF-Madrigal Pharmaceuticals Prices Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Madrigal Pharma Announces Proposed Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196

* Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia

BRIEF-Madrigal Pharmaceuticals reports qtrly loss per share $0.69

* Madrigal Pharmaceuticals reports 2017 second quarter financial results

BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH

* Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH

BRIEF-Madrigal Pharma announces $35 million private placement offering

* Madrigal pharmaceuticals announces $35 million private placement offering

BRIEF-Madrigal Pharmaceuticals says DSMC for clinical studies of MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial

* Madrigal Pharmaceuticals - on May 26, DSMC for clinical studies of co's MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial

BRIEF-Madrigal Pharmaceuticals qtrly loss per share $0.50

* Madrigal Pharmaceuticals reports 2017 first quarter financial results

BRIEF-Madrigal Pharmaceuticals Q4 loss per share $0.67

* Madrigal Pharmaceuticals reports 2016 fourth quarter and year-end financial results, reviews key corporate achievements and provides update on lead clinical-stage compound, MGL-3196

BRIEF-Madrigal Pharmaceuticals initiates Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH)

* Madrigal Pharmaceuticals announces the initiation of a Phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia (HEFH) Source text for Eikon: Further company coverage:

BRIEF-Madrigal Q3 loss per share $1.34

* Madrigal reports third quarter 2016 financial results Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up